NEURODEGENERATION program
Undisclosed Neurodegenerative Diseases
Discovery/Pre-clinicalActive
Key Facts
Indication
Undisclosed Neurodegenerative Diseases
Phase
Discovery/Pre-clinical
Status
Active
Company
About Grace Science
Grace Science is a private, pre-clinical stage biotech leveraging a decade of proprietary research on the NGLY1 pathway to develop novel therapeutics. The company's pipeline includes a lead gene therapy program for the ultra-rare NGLY1 Deficiency and exploratory small molecule programs targeting broader indications in cancer and neurodegenerative diseases. With a world-class scientific foundation, notable co-founders including a Nobel Laureate, and a strategic collaboration with Takeda, Grace Science aims to validate NGLY1 as a pivotal therapeutic target with potential impact across multiple disease areas.
View full company profile